Association of skin rash and tumor response to HER1/EGFR inhibition: does HER1 stimulated tumor growth depend on circulatory instead of paracrine ligands?
Kurbel
Sven
S
Faj
Dario
D
D000911:Antibodies, Monoclonal / Q000494:pharmacology* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D019898:Autocrine Communication; D000068818:Cetuximab; D004815:Epidermal Growth Factor / Q000097:blood / Q000502:physiology*; D066246:ErbB Receptors / Q000819:agonists / Q000037:antagonists & inhibitors / Q000502:physiology*; D000069347:Erlotinib Hydrochloride; D005076:Exanthema / Q000139:chemically induced*; D006801:Humans; D008024:Ligands; D008954:Models, Biological; D009363:Neoplasm Proteins / Q000819:agonists / Q000037:antagonists & inhibitors / Q000097:blood / Q000502:physiology*; D009369:Neoplasms / Q000188:drug therapy*; D019899:Paracrine Communication; D011799:Quinazolines / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D012867:Skin / Q000187:drug effects; D016211:Transforming Growth Factor alpha / Q000097:blood / Q000502:physiology*; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D008024:Ligands; D009363:Neoplasm Proteins; D011799:Quinazolines; D016211:Transforming Growth Factor alpha; D004815:Epidermal Growth Factor; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors; D000068818:Cetuximab